Selected research
Industry Research
Immuno-Oncology Service Industry Research Report 2026
Market perspective
The global Immuno-Oncology Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Immuno-Oncology Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Immuno-Oncology Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Immuno-Oncology Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Immuno-Oncology Service include Crown Bioscience, Bio-Techne, Abcam, WuXi AppTec, Shanghai ChemPartner, George Clinical, Laboratory Corporation of America® Holdings, Medpace and Genscript, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Immuno-Oncology Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Immuno-Oncology Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Immuno-Oncology Service Market by Company
Crown Bioscience
Bio-Techne
Abcam
WuXi AppTec
Shanghai ChemPartner
George Clinical
Laboratory Corporation of America® Holdings
Medpace
Genscript
Shanghai Novamab Biopharmaceuticals
LIDE
TransCure bioServices
Immuno-Oncology Service Segment by Type
Basic Research
Clinical Research
Immuno-Oncology Service Segment by Application
Pharmaceutical Companies
Medical Device Companies
Other
Immuno-Oncology Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Immuno-Oncology Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Basic Research
- Clinical Research
Applications
- Pharmaceutical Companies
- Medical Device Companies
- Other
Companies covered
- Crown Bioscience
- Bio-Techne
- Abcam
- WuXi AppTec
- Shanghai ChemPartner
- George Clinical
- Laboratory Corporation of America® Holdings
- Medpace
- Genscript
- Shanghai Novamab Biopharmaceuticals
- LIDE
- TransCure bioServices
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Immuno-Oncology Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Basic Research
- 2.2.3 Clinical Research
- 2.3 Immuno-Oncology Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Companies
- 2.3.3 Medical Device Companies
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Immuno-Oncology Service Breakdown Data by Type
- 3.1 Global Immuno-Oncology Service Historic Market Size by Type (2021-2026)
- 3.2 Global Immuno-Oncology Service Forecasted Market Size by Type (2027-2032)
4 Immuno-Oncology Service Breakdown Data by Application
- 4.1 Global Immuno-Oncology Service Historic Market Size by Application (2021-2026)
- 4.2 Global Immuno-Oncology Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Immuno-Oncology Service Market Perspective (2021-2032)
- 5.2 Global Immuno-Oncology Service Growth Trends by Region
- 5.2.1 Global Immuno-Oncology Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Immuno-Oncology Service Historic Market Size by Region (2021-2026)
- 5.2.3 Immuno-Oncology Service Forecasted Market Size by Region (2027-2032)
- 5.3 Immuno-Oncology Service Market Dynamics
- 5.3.1 Immuno-Oncology Service Industry Trends
- 5.3.2 Immuno-Oncology Service Market Drivers
- 5.3.3 Immuno-Oncology Service Market Challenges
- 5.3.4 Immuno-Oncology Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Immuno-Oncology Service Players by Revenue
- 6.1.1 Global Top Immuno-Oncology Service Players by Revenue (2021-2026)
- 6.1.2 Global Immuno-Oncology Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Immuno-Oncology Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Immuno-Oncology Service Head Office and Area Served
- 6.4 Global Immuno-Oncology Service Players, Product Type & Application
- 6.5 Global Immuno-Oncology Service Manufacturers Established Date
- 6.6 Global Immuno-Oncology Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Immuno-Oncology Service Market Size (2021-2032)
- 7.2 North America Immuno-Oncology Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Immuno-Oncology Service Market Size by Country (2021-2026)
- 7.4 North America Immuno-Oncology Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Immuno-Oncology Service Market Size (2021-2032)
- 8.2 Europe Immuno-Oncology Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Immuno-Oncology Service Market Size by Country (2021-2026)
- 8.4 Europe Immuno-Oncology Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Immuno-Oncology Service Market Size (2021-2032)
- 9.2 Asia-Pacific Immuno-Oncology Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Immuno-Oncology Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Immuno-Oncology Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Immuno-Oncology Service Market Size (2021-2032)
- 10.2 South America Immuno-Oncology Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Immuno-Oncology Service Market Size by Country (2021-2026)
- 10.4 South America Immuno-Oncology Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Immuno-Oncology Service Market Size (2021-2032)
- 11.2 Middle East & Africa Immuno-Oncology Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Immuno-Oncology Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Immuno-Oncology Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Crown Bioscience
- 12.1.1 Crown Bioscience Company Information
- 12.1.2 Crown Bioscience Business Overview
- 12.1.3 Crown Bioscience Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.1.4 Crown Bioscience Immuno-Oncology Service Product Portfolio
- 12.1.5 Crown Bioscience Recent Developments
- 12.2 Bio-Techne
- 12.2.1 Bio-Techne Company Information
- 12.2.2 Bio-Techne Business Overview
- 12.2.3 Bio-Techne Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.2.4 Bio-Techne Immuno-Oncology Service Product Portfolio
- 12.2.5 Bio-Techne Recent Developments
- 12.3 Abcam
- 12.3.1 Abcam Company Information
- 12.3.2 Abcam Business Overview
- 12.3.3 Abcam Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.3.4 Abcam Immuno-Oncology Service Product Portfolio
- 12.3.5 Abcam Recent Developments
- 12.4 WuXi AppTec
- 12.4.1 WuXi AppTec Company Information
- 12.4.2 WuXi AppTec Business Overview
- 12.4.3 WuXi AppTec Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.4.4 WuXi AppTec Immuno-Oncology Service Product Portfolio
- 12.4.5 WuXi AppTec Recent Developments
- 12.5 Shanghai ChemPartner
- 12.5.1 Shanghai ChemPartner Company Information
- 12.5.2 Shanghai ChemPartner Business Overview
- 12.5.3 Shanghai ChemPartner Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.5.4 Shanghai ChemPartner Immuno-Oncology Service Product Portfolio
- 12.5.5 Shanghai ChemPartner Recent Developments
- 12.6 George Clinical
- 12.6.1 George Clinical Company Information
- 12.6.2 George Clinical Business Overview
- 12.6.3 George Clinical Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.6.4 George Clinical Immuno-Oncology Service Product Portfolio
- 12.6.5 George Clinical Recent Developments
- 12.7 Laboratory Corporation of America® Holdings
- 12.7.1 Laboratory Corporation of America® Holdings Company Information
- 12.7.2 Laboratory Corporation of America® Holdings Business Overview
- 12.7.3 Laboratory Corporation of America® Holdings Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.7.4 Laboratory Corporation of America® Holdings Immuno-Oncology Service Product Portfolio
- 12.7.5 Laboratory Corporation of America® Holdings Recent Developments
- 12.8 Medpace
- 12.8.1 Medpace Company Information
- 12.8.2 Medpace Business Overview
- 12.8.3 Medpace Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.8.4 Medpace Immuno-Oncology Service Product Portfolio
- 12.8.5 Medpace Recent Developments
- 12.9 Genscript
- 12.9.1 Genscript Company Information
- 12.9.2 Genscript Business Overview
- 12.9.3 Genscript Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.9.4 Genscript Immuno-Oncology Service Product Portfolio
- 12.9.5 Genscript Recent Developments
- 12.10 Shanghai Novamab Biopharmaceuticals
- 12.10.1 Shanghai Novamab Biopharmaceuticals Company Information
- 12.10.2 Shanghai Novamab Biopharmaceuticals Business Overview
- 12.10.3 Shanghai Novamab Biopharmaceuticals Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.10.4 Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Product Portfolio
- 12.10.5 Shanghai Novamab Biopharmaceuticals Recent Developments
- 12.11 LIDE
- 12.11.1 LIDE Company Information
- 12.11.2 LIDE Business Overview
- 12.11.3 LIDE Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.11.4 LIDE Immuno-Oncology Service Product Portfolio
- 12.11.5 LIDE Recent Developments
- 12.12 TransCure bioServices
- 12.12.1 TransCure bioServices Company Information
- 12.12.2 TransCure bioServices Business Overview
- 12.12.3 TransCure bioServices Revenue in Immuno-Oncology Service Business (2021-2026)
- 12.12.4 TransCure bioServices Immuno-Oncology Service Product Portfolio
- 12.12.5 TransCure bioServices Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst